Baidu
map

JCEM:安体舒通与二甲双胍联合治疗PCOS优于单独用药

2013-07-18 desperado-c dxy

为了改善多囊卵巢综合症(PCOS)女性的治疗结局,多种药物如格列酮类、口服避孕药和抗雄激素类药物常与二甲双胍联合使用。为了比较在PCOS女性治疗中,小剂量安体舒通和二甲双胍联合用药与任一药物单用的疗效,来自印度克什米尔大学的Mohd Ashraf Ganie教授及其团队进行了一项研究,该研究发现在PCOS女性,小剂量安体舒通与二甲双胍联合用药在临床获益和依从性方面似乎优于任何一个单独用药。该研究结

为了改善多囊卵巢综合症(PCOS)女性的治疗结局,多种药物如格列酮类、口服避孕药和抗雄激素类药物常与二甲双胍联合使用。为了比较在PCOS女性治疗中,小剂量安体舒通和二甲双胍联合用药与任一药物单用的疗效,来自印度克什米尔大学的Mohd Ashraf Ganie教授及其团队进行了一项研究,该研究发现在PCOS女性,小剂量安体舒通与二甲双胍联合用药在临床获益和依从性方面似乎优于任何一个单独用药。该研究结果在线发表在2013年6月11日的《临床内分泌代谢杂志》(The journal of clinical endocrinology & metabolism)上。

该研究是在三级医疗转诊中心进行的一项开放性、随机研究。按2006年PCOS标准,从204例女性挑选合格的雄激素过多–PCOS(AE–PCOS),198例患者被随机分为3个平等组,接受为期6个月的二甲双胍(1000mg/天)、小剂量安体舒通(50mg/天)、或两药联合用药治疗。169例受试者(二甲双胍组56例;安体舒通51例;联合用药组62例)完成这个研究。在基线(0月)、干预后3月和6月测量月经周期、Ferriman–Gallway(FG)评分、体重指数(BMI)、腰臀比(WHR)、血压(BP)、促黄体生成素(LH)、卵泡刺激素(FSH)、总睾酮(T)、血糖和胰岛素敏感性指数。在每次随访期间,记录药物不良反应,并评估用药依从性。

该研究结果表明,三组基线时平均年龄和BMI具有可比性。6个月后,联合用药组与任何一个单独用药组相比,月经周期/年增加,而FG评分、血清总睾酮、血糖曲线下面积和胰岛素曲线下面积显著下降(P<0.005).三组中任何一组的体重、BMI、WHR和血压都没有明显变化。联合用药组比任何一个单独用药组有更好的依从性,并且不良反应发生率没有升高。

该研究发现,在PCOS女性,小剂量安体舒通与二甲双胍联合用药在临床获益和依从性方面似乎优于任何一个单独用药。


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2062823, encodeId=b4b32062823fe, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Mar 26 03:06:00 CST 2014, time=2014-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777442, encodeId=29cc1e77442a6, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Wed Oct 30 01:06:00 CST 2013, time=2013-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313616, encodeId=acc213136167d, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Sat Jul 20 06:06:00 CST 2013, time=2013-07-20, status=1, ipAttribution=)]
    2014-03-26 achengzhao
  2. [GetPortalCommentsPageByObjectIdResponse(id=2062823, encodeId=b4b32062823fe, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Mar 26 03:06:00 CST 2014, time=2014-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777442, encodeId=29cc1e77442a6, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Wed Oct 30 01:06:00 CST 2013, time=2013-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313616, encodeId=acc213136167d, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Sat Jul 20 06:06:00 CST 2013, time=2013-07-20, status=1, ipAttribution=)]
    2013-10-30 smallant2015
  3. [GetPortalCommentsPageByObjectIdResponse(id=2062823, encodeId=b4b32062823fe, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Mar 26 03:06:00 CST 2014, time=2014-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777442, encodeId=29cc1e77442a6, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Wed Oct 30 01:06:00 CST 2013, time=2013-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313616, encodeId=acc213136167d, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Sat Jul 20 06:06:00 CST 2013, time=2013-07-20, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map